NEW YORK – South Korean diagnostics firm Genematrix announced on Tuesday that its new human papillomavirus detection kit has received CE marking.
The NeoPlex HPV29 Detection kit can collectively detect 29 genotypes of HPV and simultaneously identify the virus genotype according to the risk of cervical cancer. It uses the firm's proprietary C-Tag multiplex RT-PCR technology.
An unnamed official for the company noted in a statement that "by reducing the turnaround time by more than an hour compared to existing products in the market, it is possible to obtain a same-day report in just half a day."
The firm also offers multiplex tests for COVID-19, respiratory tract infections, sexually transmitted infections, and gastrointestinal tract infections.
In May 2020, the firm's NeoPlex COVID-19 Detection Kit received Emergency Use Authorization from the US Food and Drug Administration.